The prevalence of chronic kidney disease (CKD) is increasing globally, and deaths attributed to CKD constituted 4.6% of all deaths in 2017.1 According to the CaReMe study, 8.3% of the population in Sweden has CKD defined as having a diagnosis, an estimated glomerular filtration rate (eGFR) <60 mL/min/1.73 m2 or urine albumin-creatinine ratio ≥30 mg/g.2 Furthermore, medical treatment due to end-stage kidney disease is costly and constitutes approximately 1% of the total medical expenditures in Sweden.3 The gene discussed is ALB; the disease is chronic kidney disease.